The first half of 2016 saw two of Europe’s mid-sized pharmaceutical companies snapping up compatriot companies while busily growing sales and profits. They’re not just taking out assets from under the noses of Europe’s Big Pharma firms, they’re showing companies can still be built on the back of good ideas and rigorous business development planning, at relatively low price-tags.
Milan, Italy-based Recordati Industria Chimica & Farmaceutica SPA is a case in point, having acquired Milan-based Italchimici SPA...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
